AstraZeneca

AstraZeneca announces historic agreement with US Government to lower the cost of medicines for American patients

Källa: MFN
Neutral

Sammanfattning

AstraZeneca har ingått ett historiskt avtal med USA:s regering för att sänka läkemedelskostnaderna för amerikanska patienter. Avtalet inkluderar prissänkningar och en betydande investering på 50 miljarder dollar i amerikansk tillverkning och FoU, vilket syftar till att säkra bolagets långsiktiga position och intäktsmål i USA.

Analys

Avtalet innebär att AstraZeneca frivilligt sänker läkemedelspriser för amerikanska patienter, inklusive rabatter på upp till 80% för vissa, vilket kan påverka intäkter och marginaler. Som motvikt åtar sig bolaget en massiv investering på 50 miljarder dollar i USA över fem år för att stärka inhemsk produktion och FoU. Denna investering är kopplad till ett mål om 80 miljarder dollar i totala intäkter till 2030, varav hälften från USA. Dessutom fördröjs tullar i tre år, vilket underlättar omställningen till amerikansk tillverkning. De exakta finansiella villkoren är konfidentiella, vilket gör en kvantifiering av nettoeffekten svår, men avtalet positionerar bolaget strategiskt i sin största marknad.

Nyckeltal

Investering i USA
50 miljarder dollar
Rabatt för patienter
upp till 80%
Intäktsmål 2030
80 miljarder dollar

Insikter

  • • Avtalet representerar en betydande strategisk anpassning till amerikansk läkemedelspolitik, vilket kan vara en modell för andra läkemedelsbolag.
  • • Den stora investeringen i USA signalerar ett långsiktigt åtagande och en satsning på framtida tillväxt i regionen.
  • • Balansen mellan priskoncessioner och strategiska fördelar är avgörande för att bedöma den långsiktiga effekten på aktieägarvärdet.
  • • Fokus på inhemsk tillverkning och FoU kan stärka bolagets leveranskedja och innovationsförmåga i USA.

Delivers on all four of President Trump's requests reducing cost of medicines.

Preserves America's role as a global powerhouse in biopharmaceuticals

innovation. AstraZeneca to invest $50bn in manufacturing and R&D to support

domestic sourcing.

Delivers on all four of President Trump's requests reducing cost of medicines. Preserves America's role as a global powerhouse in biopharmaceuticals innovation. AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing.

AstraZeneca today announces a historic agreement with President Donald J. Trump's administration to lower the cost of prescription medicines for American patients while preserving America's cutting-edge biopharmaceutical innovation.

At a landmark event at the White House, AstraZeneca CEO Pascal Soriot joined President Trump and members of his Administration to confirm the Company voluntarily met all requests set out in the President's 31 July letter. The Company agrees to a range of measures which will enable American patients to access medicines at prices that are equalized with those available in wealthy countries.

As part of the agreement, AstraZeneca will provide Direct-to-Consumer (DTC) sales to eligible patients with prescriptions for chronic diseases at a discount of up to 80% off list prices. AstraZeneca will participate in the TrumpRx.gov direct purchasing platform, which will allow patients to purchase medicines at a reduced cash price from AstraZeneca.

AstraZeneca has also reached an agreement with the US Department of Commerce to delay Section 232 tariffs for three years, enabling the Company to fully onshore medicines manufacturing so that all of its medicines sold in America are made in America. This will be achieved through the Company's recently announced $50 billion investment in US medicines manufacturing and R&D over the next five years to help deliver $80 billion in Total Revenue by 2030, 50% of which is expected to be generated in the US.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Every year AstraZeneca treats millions of Americans living with cancer and chronic diseases and, as a result of today's agreement, many patients will access life-changing medicines at lower prices. This new approach also helps safeguard America's pioneering role as a global powerhouse in innovation and developing the next generation of medicines. It is now essential other wealthy countries step up their contribution to fund innovation."

AstraZeneca's commitment to the US and American patients is further reflected in the Company's largest single investment in a manufacturing facility to date, where the Company broke ground yesterday in Virginia. This facility will support AstraZeneca's weight management and metabolic portfolio and our leading antibody drug conjugate cancer pipeline. Additionally, a newly expanded manufacturing facility in Coppell, Texas, will officially open next week. Looking ahead, AstraZeneca will open a cell therapy manufacturing facility in Rockville, Maryland early next year and its second major R&D centre in Cambridge, Massachusetts will open in late 2026.

The US is AstraZeneca's largest market by sales and is also home to 19 R&D, manufacturing and commercial sites. The Company's US workforce exceeds more than 25,000 people and supports more than 100,000 jobs overall across the country. In 2025, AstraZeneca created approximately $20 billion of overall value to the American economy.

Notes

AstraZeneca's agreement with US Government

This is the second agreement that a pharmaceutical company has made with the US Department of Health and Human Services to lower the cost of medicines for American patients in the past two weeks. Specific terms of this agreement remain confidential.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. The contents of AstraZeneca's website do not form part of this document and no one should rely on such websites or the contents thereof in reading this document.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Fler nyheter från AstraZeneca

Relaterade pressmeddelanden och bolagshändelser från samma bolag.

Se bolagssidan